Given the early promise of finally targeting KRAS indirectly through this approach, there was a randomised controlled trial, the SELECT-1 trial, which compared docetaxel alone to a combination with selumetinib, a MEK inhibitor in patients with KRAS-mutant lung adenocarcinoma. Here, MAP2K7 is linked to lung adenocarcinoma.